Suven Life Sciences today said that its new chemical entity (NCE) has entered the phase 1 of clinical trial in the US.
In a BSE filing, Suven Life Sciences said its “NCE SUVN-3031 has commenced Phase 1 clinical trial in USA.”
The company added that the NCE used for the treatment of cognitive dysfunction associated with Alzheimer’s disease/Schizophrenia has completed all the preclinical, safety and early toxicological studies, and GLP toxicological studies and was submitted for investigational new drug application to conduct phase 1 clinical trial.
Commenting on the development, Suven Life Science CEO Venkat Jasti said: “We are very pleased that the second compound from our pipeline of molecules in CNS has moved into clinical trial that is being developed for cognitive disorders in Alzheimer’s and Schizophrenia with high unmet medical need which has huge market potential globally.”
Suven Life Sciences has 11 internally discovered therapeutic drug candidates currently in pre-clinical stage of development, targeting conditions such as dementia, major depressive disorder (MDD), Huntington’s disease, Parkinson’s disease and obesity.